Uncategorized
STAAR Surgical Reports First Quarter 2018 Results; Revenue Increases 33 Percent on Accelerating EVO Visian ™ ICL Momentum
MONROVIA, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye today reported financial results for the first quarter ended March 30, 2018. First Quarter 2018 Overview Net Sales of $27.1 Million Up 33% from the Prior Year Quarter ICL Sales Up 39% and Units Up 41% from the Prior Year Quarter Other Sales Up 17% from the Prior Year Quarter Gross Margin at 71.7% of Sales from 7